Tirzepatide
Tirzepatide is a synthetic peptide that acts as a dual agonist of the GIP and GLP-1 receptors.
Side-by-side price comparison for GLP-1, GIP and glucagon receptor research peptides — Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Survodutide and Mazdutide. Prices normalized to dollars per milligram across 34 vendors.
| Peptide | Vendors | Lowest $/mg |
|---|---|---|
| Tirzepatide | 14 | $2.50/mg |
| Semaglutide | 17 | $3.33/mg |
| Retatrutide | 15 | $5.17/mg |
| Mazdutide | 9 | $5.90/mg |
| Survodutide | 8 | $7.90/mg |
| Cagrilintide | 20 | $8.20/mg |
Tirzepatide is a synthetic peptide that acts as a dual agonist of the GIP and GLP-1 receptors.
Semaglutide is a GLP-1 receptor agonist peptide — a modified analogue of the glucagon-like peptide-1 hormone.
Retatrutide is an experimental peptide that acts as a triple receptor agonist (GIP, GLP-1, and glucagon), under pharmaceutical development.
Mazdutide is an experimental peptide acting as a dual GLP-1/glucagon receptor agonist, under pharmaceutical development.
Survodutide is an experimental peptide acting as a dual glucagon/GLP-1 receptor agonist, under pharmaceutical development.
Cagrilintide is a long-acting synthetic analogue of the hormone amylin, studied as an experimental compound, including in combination with semaglutide.
Incretin and metabolic research peptides — GLP-1, GIP and glucagon receptor agonists studied in metabolic research. Compare prices by $/mg.
Prices are pulled directly from each vendor's storefront and normalized to dollars per milligram so differently-sized vials can be compared on equal terms. The "cheapest vendor" highlighted for each compound is whoever currently posts the lowest $/mg — not a recommendation, just the math.
For research use only. These compounds are not approved by the FDA for human consumption. This page is a price index, not medical advice. Always confirm current pricing on each vendor's site before purchase.